San Francisco-based iRhythm presented the data at the Heart Rhythm Society’s annual meeting, Heart Rhythm 2023, in New Orleans. Data supports ambulatory cardiac monitoring of up to 14 days with the company’s Zio XT. It demonstrated increased diagnostic yield and improved diagnostic accuracy of ventricular arrhythmias across a variety of patient populations.
“These studies thematically showcase the value of iRhythm’s Zio products and services — in particular for identifying ventricular arrhythmias for risk stratification and disease management,” said Dr. Mintu Turakhia, iRhythm chief medical officer, chief scientific officer and EVP, product innovation. “The findings have important clinical and scientific implications, and they further demonstrate the strength of our technolo…